Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in pediatric relapsed/refractory solid tumors, lymphoma, and CNS tumors
NCT02793466Phase 1Completed
- Start
- Jul 2016
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in solid tumor, lymphoma and central nervous system tumor. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 4 more. Started Jul 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
solid tumorlymphomacentral nervous system tumor
Beyond the preview
Go deeper on NCT02793466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793466.